Brian Savage, Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd., filed a Form 4 on September 22, 2026, reporting option exercises and open-market sales of ordinary shares that took place on September 18, 2026.

Key Highlights

  • Option exercise: Brian Savage exercised stock options (transaction code M) covering 4,503 ordinary shares at an exercise price of $34.70 per share on September 18, 2026.
  • Share sales: Savage disposed of a total of 7,342 ordinary shares across three separate sell transactions (code S) on September 18, 2026, at prices of $38.69, a weighted average of $39.145, and $38.7038 per share.
  • Weighted average disclosure: The 2,525-share sale at $39.145 was executed in multiple transactions at prices ranging from $39.14 to $39.155, inclusive, according to the filing.
  • Remaining ownership: Following all reported transactions, Savage directly held 8,500 ordinary shares.
  • Options fully exercised: The exercised stock options, originally granted on March 3, 2017, show a remaining balance of 0 derivative securities after the transaction.
  • Issuer: Teva Pharmaceutical Industries Ltd., trading on NYSE as TEVA (NYSE:TEVA).

Savage's Option Exercise and Share Dispositions at Teva Pharmaceutical

According to the Form 4 filing, Brian Savage, serving as Interim Chief Legal Officer of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), executed a series of transactions on September 18, 2026. He first exercised stock options covering 4,503 ordinary shares at an exercise price of $34.70 per share, bringing his total beneficial ownership to 15,842 shares at that point. The options had been granted on March 3, 2017, with vesting tranches of 1,125 shares on each of March 3, 2018, March 3, 2019, and March 3, 2020, and 1,128 shares on March 3, 2021, per the filing's footnotes.

Following the exercise, the filing reports three separate sell transactions. Savage disposed of 4,503 shares at $38.69, then 2,525 shares at a weighted average price of $39.145 (with individual transaction prices ranging from $39.14 to $39.155, inclusive), and finally 314 shares at $38.7038. All three sales carried transaction code S and were reported as direct ownership. After these dispositions, Savage's directly held position stood at 8,500 ordinary shares, as stated in the filing.

The Form 4 was signed by Dov Bergwerk as attorney-in-fact for Brian P. Savage and filed on September 22, 2026. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934. No Rule 10b5-1 plan checkbox was indicated as checked in the filing.

What Was Disclosed

The filing discloses an option exercise of 4,503 Teva ordinary shares at $34.70 and subsequent open-market sales totaling 7,342 shares on September 18, 2026, leaving Savage with a direct beneficial ownership of 8,500 ordinary shares.